US 11,998,634 B2
Micro- or nano emulsions including anticancer drugs
Ranjita Sahoo, Goch (DE)
Assigned to CAPNOPHARM GMBH, Tübingen (DE)
Appl. No. 17/414,065
Filed by CAPNOPHARM GMBH, Tübingen (DE)
PCT Filed Dec. 6, 2019, PCT No. PCT/EP2019/083938
§ 371(c)(1), (2) Date Jun. 15, 2021,
PCT Pub. No. WO2020/126539, PCT Pub. Date Jun. 25, 2020.
Claims priority of application No. 18213995 (EP), filed on Dec. 19, 2018.
Prior Publication US 2022/0054413 A1, Feb. 24, 2022
Int. Cl. A61K 9/107 (2006.01); A61K 31/12 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/704 (2006.01); A61K 33/243 (2019.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/26 (2006.01)
CPC A61K 9/107 (2013.01) [A61K 31/12 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/704 (2013.01); A61K 33/243 (2019.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/26 (2013.01)] 20 Claims
 
1. An emulsion formulation comprising:
(a) 1 to 15 wt. % of polyethylene glycol (15)-hydroxystearate,
(b) 0.3 to 10 wt. % of polyglyceryl-3 oleate,
(c) at least one anti-cancer drug selected from oxaliplatin, cisplatin, doxorubicin, or paclitaxel,
(d) optionally, polysorbate, and
(e) water,
wherein the emulsion is an oil-in-water micro- or nanoemulsion and all percentages by weight are based on a total weight of the emulsion formulation.